EP380: 7 Big Reasons Medicare Drug Price Negotiation Actually Happened This Time Around—What Changed? With Mark Miller, PhD

7 Big Reasons Medicare Drug Price Negotiation Actually Happened This Time Around, With Mark Miller, PhD. Medicare Can Now Negotiate Drug Prices—Here's the Political Constellation That Made It Happen. Episode 380.

Stacey Richter talks with Mark Miller, PhD, EVP of healthcare at Arnold Ventures and former longtime executive director of MedPAC, about the seven converging factors that finally got Medicare drug price negotiation signed into law after a decade of failed attempts.

WHAT YOU'LL LEARN

✅ Why growing public sensitivity to healthcare costs in general made Pharma an easy-to-spot target

✅ How non-industry-sponsored research began undercutting Pharma's R&D cost claims

✅ Why the distinction between breakthrough innovation and me-too drugs started mattering to policymakers

✅ How the tension between future innovation and today's access worked against Pharma's messaging

✅ Why Pharma's talking points stayed the same even as the political landscape shifted underneath them

✅ What else got packaged into the law, including the $2,000 Part D out-of-pocket cap and inflation rebates

WHY THIS MATTERS

For a decade, pundits predicted a healthcare-cost reckoning that never quite arrived. Miller's seven-factor breakdown explains why 2022 was different—and understanding the political mechanics behind drug price negotiation matters for anyone trying to predict what other structural changes in healthcare could actually become law next.

MENTIONED IN THIS EPISODE

No past-episode citations in this episode's timestamped chapter list.

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

📺 Subscribe to our YouTube channel

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

04:45 Why did Medicare's ability to negotiate on drug pricing happen now?

06:35 What's different about the drug market today that allowed Medicare to gain the ability to negotiate drug pricing?

12:08 How has innovation played into drug price negotiations?

12:40 "If you limit profits, you can end up limiting innovation."

14:03 Why was the distinction between more drugs and innovative drugs important to changing the landscape of the drug market?

15:49 More versus new and future versus now in the drug market.

19:59 "As the landscape was shifting, Pharma didn't shift with it."

23:00 How did voters change the landscape in drug pricing?

24:39 "Pharma did not have exclusive control over the patients' voice."

29:59 "The industry would largely like to just stick with the patents that they have."

30:16 "Of course, it's competition that ultimately drives innovation."

31:30 "This is an exquisitely complicated market."